Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status

Summary

Diabetes increases cardiovascular risk and reduces pharmacodynamic response to some oral antiplatelet drugs. This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patients with vs without diabetes in the PEGASUS-TIMI 54 platelet function substudy. Out of 180 patients studied, 58 patients were randomised to and had received at least four weeks of ticagrelor 60 mg bid, with 20 (34 %) having diabetes, 58 patients received ticagrelor 90 mg bid, with 12 (21 %) having diabetes, and 64 patients received placebo, with 18 (28 %) having diabetes. Blood was sampled pre- and 2 hours post-maintenance dose. In patients treated with ticagrelor 60 mg bid, on-treatment platelet reactivity to ADP, as determined by light transmission aggregometry (LTA), VerifyNow and VASP, was similar in patients with vs without diabetes (LTA post-dose, ADP 20 ?M: 29 ± 14 vs 34 ± 10 %, respectively; p = 0.19). A consistent inhibitory effect of ticagrelor 60 mg bid was observed pre- and post-dose regardless of diabetes status, even in insulin-treated patients. Patients with diabetes did not have an increased incidence of high platelet reactivity in either ticagrelor group. Platelet reactivity was similar in patients with diabetes treated with ticagrelor 60 mg vs 90 mg bid. Pharmacokinetics of ticagrelor were not affected by diabetes status. In conclusion, ticagrelor 60 mg bid is equally effective at reducing platelet reactivity in patients with and without diabetes, yielding a consistently high level of platelet inhibition regardless of diabetes status.

Keywords

Coronary artery disease - acute coronary syndromes - pharmacology - pharmacodynamics

• References

• 1 Donahoe SM, Stewart GC, McCabe CH. et al. Diabetes and mortality following acute coronary syndromes.. J Am Med Assoc 2007; 298: 765-775
• 2 Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome.. Circulation 2011; 123: 798-813
• 3 Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome.. Nat Rev Cardiol 2014; 12: 30-47
• 4 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction.. N Engl J Med 2015; 372: 1791-1800
• 5 Udell JA, Bonaca MP, Collet J-P. et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.. Eur Heart J 2016; 37: 390-399
• 6 Capodanno D, Patel A, Dharmashankar K. et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.. Circulation: Cardiovascular Interventions 2011; 04: 180-187
• 7 Mortensen SB, Larsen SB, Grove EL. et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.. Thromb Res 2010; 126: e318-322
• 8 Christensen KH, Grove EL, Würtz M. et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.. Platelets 2014; 26: 230-235
• 9 Angiolillo DJ, Jakubowski JA, Ferreiro JL. et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.. J Am Coll Cardiol 2014; 64: 1005-1014
• 10 Carreras ET, Hochholzer W, Frelinger AL III. et al. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel.. Thromb Haemost 2016; 116: 1-9
• 11 Clavijo LC, Maya J, Carlson G. et al. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.. Cardiovasc Revasc Med 2015; 16: 450-454
• 12 Price MJ. Diabetes mellitus and clopidogrel response variability.. J Am Coll Car-diol 2014; 64: 1015-1018
• 13 Bhatt DL, Bonaca MP, Bansilal S. et al. Reduction in Ischemic Events With Ti-cagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.. J Am Coll Cardiol 2016; 67: 2732-2740
• 14 Storey RF, Angiolillo DJ, Bonaca MP. et al. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.. J Am Coll Cardiol 2016; 67: 1145-1154
• 15 Storey RF, Angiolillo DJ, Patil SB. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol 2010; 56: 1456-1462
• 16 Tantry US, Bonello L, Aradi D. et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding.. J Am Coll Cardiol 2013; 62: 2261-2273
• 17 Aradi D, Storey RF, Komócsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.. Eur Heart J 2013; 35: 209-215
• 18 Bonello L, Tantry US, Marcucci R. et al. Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphos-phate.. J Am Coll Cardiol 2010; 56: 919-933
• 19 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.. J Am Coll Cardiol 2003; 41: 961-965
• 20 Kazi DS, Leong TK, Chang TI. et al. Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous Coronary Intervention.. J Am Coll Cardiol 2015; 65: 1411-1420
• 21 Nardin M, Verdoia M, Sartori C. et al. Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.. Thromb Res 2016; 143: 45-49
• 22 Alexopoulos D, Vogiatzi C, Stavrou K. et al. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.. Cardiovasc Diabetol 2015; 14: 68.
• 23 Harmsze AM, Van Werkum JW, Moral F. et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients.. Platelets 2010; 22: 98-102
• 24 Franchi F, Rollini F, Aggarwal N. et al. Pharmacodynamic Comparison of Prasu-grel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.. Circulation 2016; 134: 780-792
• 25 Tamminen M, Lassila R, Westerbacka J. et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.. Int J Obes Relat Metab Disord 2003; 27: 907-911
• 26 Neergaard-Petersen S, Hvas AM, Kristensen SD. et al. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.. Thromb Haemost 2014; 112: 1142-1150
• 27 King R, Tiede C, Simmons K. et al. Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes.. Lancet 2015; 385 (Suppl. 01) S57.
• 28 Rollini F, Tello-Montoliu A, Patel R. et al. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.. J Thromb Thrombolysis 2014; 37: 131-138
• 29 Cattaneo M, Schulz R, Nylander S.. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.. J Am Coll Cardiol 2014; 63: 2503-2509
• 30 Bonello L, Laine M, Kipson N. et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.. J Am Coll Cardiol 2014; 63: 872-877